Literature DB >> 18458846

Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells.

Keiko Iwamoto1, Keishi Kanno, Hideyuki Hyogo, Sho-Ichi Yamagishi, Masayoshi Takeuchi, Susumu Tazuma, Kazuaki Chayama.   

Abstract

BACKGROUND: Advanced glycation end products (AGEs), final reaction products of protein with sugars, are known to contribute to diabetes-related complications. We have recently demonstrated high levels of serum AGEs in patients with nonalcoholic steatohepatitis (NASH). However, direct evidence for the participation of AGEs in hepatic inflammation and fibrosis has not been shown. To explore the pathogenesis of NASH, we examined the biological infl uence of AGEs on hepatic stellate cells (HSCs) in vitro.
METHODS: An established human HSC line, LI90, was exposed to a glyceraldehyde-derived-AGE (glycer-AGE), and the phenotypical changes of the LI90 cells were investigated. Intracellular formation of reactive oxygen species (ROS) was measured using a fl uorescent probe. Cell proliferation was examined by MTS assay. Fibrogenic marker gene expression was analyzed by quantitative real-time polymerase chain reaction. The production of monocyte chemoattractant protein 1 (MCP-1) was assessed by enzyme-linked immunosorbent assay.
RESULTS: The expression of AGE receptor was confirmed in LI90 cells at the mRNA and protein levels. In addition to increasing intracellular ROS generation, glycer-AGE upregulated fibrogenic genes such as those encoding for alpha-smooth muscle actin, transforming growth factor-beta1, and collagen type Ialpha2. The expression of MCP-1 mRNA in LI90 cells as well as its secretion into the culture medium was significantly increased in response to AGEs. These changes were attenuated by treatment with the antioxidant N-acetylcysteine.
CONCLUSIONS: These data indicate that AGEs induce ROS generation and intensify the proliferation and activation of HSCs, supporting the possibility that antioxidants may represent a promising treatment for prevention of the development of hepatic fibrosis in NASH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18458846     DOI: 10.1007/s00535-007-2152-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  35 in total

1.  Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.

Authors:  J E Lavine
Journal:  J Pediatr       Date:  2000-06       Impact factor: 4.406

2.  Effects of herbal compound 861 on human hepatic stellate cell proliferation and activation.

Authors:  Lin Wang; Jian Wang; Bao-En Wang; Pei-Gen Xiao; Yan-Jiang Qiao; Xue-Hai Tan
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

3.  Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells.

Authors:  F Marra; R G Romanelli; C Giannini; P Failli; S Pastacaldi; M C Arrighi; M Pinzani; G Laffi; P Montalto; P Gentilini
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria.

Authors:  K Hensley; Y Kotake; H Sang; Q N Pye; G L Wallis; L M Kolker; T Tabatabaie; C A Stewart; Y Konishi; D Nakae; R A Floyd
Journal:  Carcinogenesis       Date:  2000-05       Impact factor: 4.944

Review 5.  Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo.

Authors:  M Takeuchi; Z Makita
Journal:  Curr Mol Med       Date:  2001-07       Impact factor: 2.222

6.  Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.

Authors:  John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust
Journal:  J Hepatol       Date:  2006-03-20       Impact factor: 25.083

7.  Advanced glycosylation end products induce NF-kappaB dependent iNOS expression in RAW 264.7 cells.

Authors:  Chih-Hsiung Wu; Chao-Ming Huang; Chien-Huang Lin; Yuan-Sun Ho; Chien-Ming Chen; Horng-Mo Lee
Journal:  Mol Cell Endocrinol       Date:  2002-08-30       Impact factor: 4.102

8.  TAGE (toxic AGEs) hypothesis in various chronic diseases.

Authors:  M Takeuchi; S Yamagishi
Journal:  Med Hypotheses       Date:  2004       Impact factor: 1.538

9.  Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.

Authors:  Nobuyuki Sasaki; Masayoshi Takeuchi; Hiroshi Chowei; Seiji Kikuchi; Yorihide Hayashi; Norihito Nakano; Hiroshi Ikeda; Sho-ichi Yamagishi; Tetsuyuki Kitamoto; Toshikazu Saito; Zenji Makita
Journal:  Neurosci Lett       Date:  2002-06-28       Impact factor: 3.046

10.  Respiratory chain components involved in the glycerophosphate dehydrogenase-dependent ROS production by brown adipose tissue mitochondria.

Authors:  Marek Vrbacký; Zdenek Drahota; Tomás Mrácek; Alena Vojtísková; Pavel Jesina; Pavel Stopka; Josef Houstek
Journal:  Biochim Biophys Acta       Date:  2007-05-13
View more
  38 in total

1.  Effects of the dihydrolipoyl histidinate zinc complex against carbon tetrachloride-induced hepatic fibrosis in rats.

Authors:  Yuichiro Kawano; Masayuki Ohta; Yukio Iwashita; Yoko Komori; Masafumi Inomata; Seigo Kitano
Journal:  Surg Today       Date:  2014-09       Impact factor: 2.549

2.  Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.

Authors:  Hiromi Kan; Sho-ichi Yamagishi; Ayako Ojima; Kei Fukami; Seiji Ueda; Masayoshi Takeuchi; Hideyuki Hyogo; Hiroshi Aikata; Kazuaki Chayama
Journal:  J Clin Lab Anal       Date:  2014-09-23       Impact factor: 2.352

Review 3.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

4.  Role of the receptor for advanced glycation end products in hepatic fibrosis.

Authors:  Christina Lohwasser; Daniel Neureiter; Yury Popov; Michael Bauer; Detlef Schuppan
Journal:  World J Gastroenterol       Date:  2009-12-14       Impact factor: 5.742

5.  Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

Authors:  Yuki Kimura; Hideyuki Hyogo; Sho-ichi Yamagishi; Masayoshi Takeuchi; Tomokazu Ishitobi; Yoshitaka Nabeshima; Koji Arihiro; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2010-01-30       Impact factor: 7.527

Review 6.  Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo.

Authors:  Youcai Tang
Journal:  Dig Dis Sci       Date:  2014-12-23       Impact factor: 3.199

7.  Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.

Authors:  Takashi Nakahara; Hideyuki Hyogo; Atsushi Ono; Yuko Nagaoki; Tomokazu Kawaoka; Daiki Miki; Masataka Tsuge; Nobuhiko Hiraga; Clair Nelson Hayes; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hiroshi Aikata; Hidenori Ochi; Hiromi Abe-Chayama; Hisako Furusho; Tomoaki Shintani; Hidemi Kurihara; Mutsumi Miyauchi; Takashi Takata; Koji Arihiro; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2017-07-24       Impact factor: 7.527

Review 8.  Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Akiko Sakasai-Sakai; Takanobu Takata; Tadashi Ueda; Mikihiro Tsutsumi; Hideyuki Hyogo; Sho-Ichi Yamagishi
Journal:  World J Hepatol       Date:  2014-12-27

9.  The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity.

Authors:  Jun-ichi Takino; Yuka Kobayashi; Masayoshi Takeuchi
Journal:  J Gastroenterol       Date:  2010-01-19       Impact factor: 7.527

10.  Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients.

Authors:  Hideyuki Hyogo; Sho-Ichi Yamagishi; Sayaka Maeda; Kei Fukami; Seiji Ueda; Seiya Okuda; Takashi Nakahara; Yuki Kimura; Tomokazu Ishitobi; Kazuaki Chayama
Journal:  Clin Exp Med       Date:  2012-11-23       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.